Such an approach is employed in an ongoing phase II trial (NCT01676259), where patients with pancreatic cancer receive intratumoural injection of a KRAS-G12D-specific siRNA in a biodegradable matrix (allowing prolonged drug release) in combination with systemic chemotherapy [124]. Here, KRAS is linked to familial pancreatic carcinoma.